Login to Your Account

Ardelyx IBS drug in CKD runs into diarrhea snag, but efficacy's favorable

By Randy Osborne
Staff Writer

Monday, February 2, 2015

Tenapanor, the NHE3 sodium transporter inhibitor that yielded positive phase IIb data last fall in constipation-predominant irritable bowel syndrome (IBS-C) for Ardelyx Inc. and partner Astrazeneca plc, hit its efficacy endpoint in a second indication, but disappointed investors with "distinctly" higher-than-expected instances of diarrhea.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription